The 100 top-cited articles in diabetic kidney disease: a bibliometric analysis

References

• Tuttle KR, Bakris GL, Bilous RW, et al. Diabetic kidney disease: a report from an ADA Consensus Conference. Diabetes Care. 2014;37(10):2864–2883.
   PubMed Web of Science ®Google Scholar
• Giugliano D, De Nicola L, Maiorino MI, et al. Type 2 diabetes and the kidney: insights from cardiovascular outcome trials. Diabetes Obes Metab. 2019;21(8):1790–1800.
   PubMed Web of Science ®Google Scholar
• Moed HF. New developments in the use of citation analysis in research evaluation. Arch Immunol Ther Exp (Warsz). 2009;57(1):13–18.
   PubMed Web of Science ®Google Scholar
• Marx W, Schier H, Wanitschek M. Citation analysis using online databases: feasibilities and shortcomings. Scientometrics. 2001;52(1):59–82.
   Web of Science ®Google Scholar
• Mann JF, Schmieder RE, McQueen M, et al. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet. 2008;372(9638):547–553.
   PubMed Web of Science ®Google Scholar
• Palevsky PM, Zhang JH, Seliger SL, et al. Incidence, severity, and outcomes of AKI associated with dual renin-angiotensin system blockade. Clin J Am Soc Nephrol. 2016;11(11):1944–1953.
   PubMed Web of Science ®Google Scholar
• Parving HH, Persson F, Lewis JB, et al. Aliskiren combined with losartan in type 2 diabetes and nephropathy. N Engl J Med. 2008;358(23):2433–2446.
   PubMed Web of Science ®Google Scholar
• Fried LF, Emanuele N, Zhang JH, et al. Combined angiotensin inhibition for the treatment of diabetic nephropathy. N Engl J Med. 2013;369(20):1892–1903.
   PubMed Web of Science ®Google Scholar
• Yale JF, Bakris G, Cariou B, et al. Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease. Diabetes Obes Metab. 2013;15(5):463–473.
   PubMed Web of Science ®Google Scholar
• Wanner C, Inzucchi SE, Lachin JM, et al. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med. 2016;375(4):323–334.
   PubMed Web of Science ®Google Scholar
• Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377(7):644–657.
   PubMed Web of Science ®Google Scholar
• Mann JFE, Orsted DD, Brown-Frandsen K, et al. Liraglutide and renal outcomes in type 2 diabetes. N Engl J Med. 2017;377(9):839–848.
   PubMed Web of Science ®Google Scholar
• Kodera R, Shikata K, Kataoka HU, et al. Glucagon-like peptide-1 receptor agonist ameliorates renal injury through its anti-inflammatory action without lowering blood glucose level in a rat model of type 1 diabetes. Diabetologia. 2011;54(4):965–978.
   PubMed Web of Science ®Google Scholar
• InCites Clarivate; 2020; [cited 2020 Dec 30]. Available from: https://clarivate.com/webofsciencegroup/solutions/incites/
   Google Scholar
• Dmytriw AA, Hui N, Singh T, et al. Bibliometric evaluation of systematic review and meta analyses published in the top 5 "high-impact" radiology journals. Clin Imaging. 2021;71:52–62.
   PubMed Web of Science ®Google Scholar
• Azer SA, Azer S. Top-cited articles in medical professionalism: a bibliometric analysis versus Altmetric scores. BMJ Open. 2019;9(7):e029433.
   PubMed Web of Science ®Google Scholar
• Liu C, Yuan Q, Mao Z, et al. The top 100 most cited articles on rhabdomyolysis: a bibliometric analysis. Am J Emerg Med. 2020;38(9):1754–1759.
   PubMed Web of Science ®Google Scholar
• Azer SA, Azer S. What can we learn from top-cited articles in inflammatory bowel disease? A bibliometric analysis and assessment of the level of evidence. BMJ Open. 2018;8(7):e021233.
   PubMed Web of Science ®Google Scholar
• R Core Team. R: a language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing; 2020. Available from: https://www.R-project.org/
   Google Scholar
• Hunter JD. Matplotlib: a 2D graphics environment. Comput Sci Eng. 2007;9(3):90–95.
   Web of Science ®Google Scholar
• The Pandas Development Team, pandas-dev/pandas: Pandas; 2020; [cited Dec 26]. Available from:
   Google Scholar
• VOSviewer – visualizing scientific landscapes; 2020; [cited 2020 Dec 30]. Available from: https://www.vosviewer.com/
   Google Scholar
• Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001;345(12):861–869.
   PubMed Web of Science ®Google Scholar
• Parving HH, Lehnert H, Brochner-Mortensen J, et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med. 2001;345(12):870–878.
   PubMed Web of Science ®Google Scholar
• Steffes MW, Chavers BM, Molitch ME, et al. Sustained effect of intensive treatment of type 1 diabetes mellitus on development and progression of diabetic nephropathy – The Epidemiology of Diabetes Interventions and Complications (EDIC) study. JAMA. 2003;290(16):2159–2167.
   PubMed Web of Science ®Google Scholar
• de Zeeuw D, Remuzzi G, Parving HH, et al. Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL. Kidney Int. 2004;65(6):2309–2320.
   PubMed Web of Science ®Google Scholar
• Cherney DZI, Perkins BA, Soleymanlou N, et al. Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus. Circulation. 2014;129(5):587–597.
   PubMed Web of Science ®Google Scholar
• de Zeeuw D, Remuzzi G, Parving HH, et al. Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy. Circulation. 2004;110(8):921–927.
   PubMed Web of Science ®Google Scholar
• Kato M, Zhang J, Wang M, et al. MicroRNA-192 in diabetic kidney glomeruli and its function in TGF-beta-induced collagen expression via inhibition of E-box repressors. Proc Natl Acad Sci U S A. 2007;104(9):3432–3437.
   PubMed Web of Science ®Google Scholar
• Perkins BA, Ficociello LH, Silva KH, et al. Regression of microalbuminuria in type 1 diabetes. N Engl J Med. 2003;348(23):2285–2293.
   PubMed Web of Science ®Google Scholar
• de Zeeuw D, Akizawa T, Audhya P, et al. Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease. N Engl J Med. 2013;369(26):2492–2503.
   PubMed Web of Science ®Google Scholar
• de Zeeuw D, Agarwal R, Amdahl M, et al. Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): a randomised controlled trial. Lancet. 2010;376(9752):1543–1551.
   PubMed Web of Science ®Google Scholar
• Kato M, Putta S, Wang M, et al. TGF-beta activates Akt kinase through a microRNA-dependent amplifying circuit targeting PTEN. Nat Cell Biol. 2009;11(7):881–889.
   PubMed Web of Science ®Google Scholar
• Ichihara A, Hayashi M, Kaneshiro Y, et al. Inhibition of diabetic nephropathy by a decoy peptide corresponding to the "handle" region for nonproteolytic activation of prorenin. J Clin Invest. 2004;114(8):1128–1135.
   PubMed Web of Science ®Google Scholar
• Keane WF, Brenner BM, de Zeeuw D, et al. The risk of developing end-stage renal disease in patients with type 2 diabetes and nephropathy: the RENAAL Study. Kidney Int. 2003;63(4):1499–1507.
   PubMed Web of Science ®Google Scholar
• Oldfield MD, Bach LA, Forbes JM, et al. Advanced glycation end products cause epithelial-myofibroblast transdifferentiation via the receptor for advanced glycation end products (RAGE). J Clin Invest. 2001;108(12):1853–1863.
   PubMed Web of Science ®Google Scholar
• Parving HH, Lewis JB, Ravid M, et al. Prevalence and risk factors for microalbuminuria in a referred cohort of type II diabetic patients: a global perspective. Kidney Int. 2006;69(11):2057–2063.
   PubMed Web of Science ®Google Scholar
• Steffes MW, Schmidt D, McCrery R, et al. Glomerular cell number in normal subjects and in type 1 diabetic patients. Kidney Int. 2001;59(6):2104–2113.
   PubMed Web of Science ®Google Scholar
• Mann JFE, Green D, Jamerson K, et al. Avosentan for overt diabetic nephropathy. J Am Soc Nephrol. 2010;21(3):527–535.
   PubMed Web of Science ®Google Scholar
• Coughlan MT, Thorburn DR, Penfold SA, et al. RAGE-induced cytosolic ROS promote mitochondrial superoxide generation in diabetes. J Am Soc Nephrol. 2009;20(4):742–752.
   PubMed Web of Science ®Google Scholar
• Perkins BA, Ficociello LH, Ostrander BE, et al. Microalbuminuria and the risk for early progressive renal function decline in type 1 diabetes. J Am Soc Nephrol. 2007;18(4):1353–1361.
   PubMed Web of Science ®Google Scholar
• Tikellis C, Johnston CI, Forbes JM, et al. Characterization of renal angiotensin-converting enzyme 2 in diabetic nephropathy. Hypertension. 2003;41(3):392–397.
   PubMed Web of Science ®Google Scholar
• Hovind P, Tarnow L, Rossing K, et al. Decreasing incidence of severe diabetic microangiopathy in type 1 diabetes. Diabetes Care. 2003;26(4):1258–1264.
   PubMed Web of Science ®Google Scholar
• Wang B, Koh P, Winbanks C, et al. miR-200a prevents renal fibrogenesis through repression of TGF-β2 expression. Diabetes. 2011;60(1):280–287.
   PubMed Web of Science ®Google Scholar
• Putta S, Lanting L, Sun GD, et al. Inhibiting microRNA-192 ameliorates renal fibrosis in diabetic nephropathy. J Am Soc Nephrol. 2012;23(3):458–469.
   PubMed Web of Science ®Google Scholar
• Eijkelkamp WBA, Zhang ZX, Remuzzi G, et al. Albuminuria is a target for renoprotective therapy independent from blood pressure in patients with type 2 diabetic nephropathy: post hoc analysis from the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial. J Am Soc Nephrol. 2007;18(5):1540–1546.
   PubMed Web of Science ®Google Scholar
• Bakris GL, Agarwal R, Chan JC, et al. Effect of finerenone on albuminuria in patients with diabetic nephropathy: a randomized clinical trial. JAMA. 2015;314(9):884–894.
   PubMed Web of Science ®Google Scholar
• Thallas-Bonke V, Thorpe SR, Coughlan MT, et al. Inhibition of NADPH oxidase prevents advanced glycation end product-mediated damage in diabetic nephropathy through a protein kinase C-alpha-dependent pathway. Diabetes. 2008;57(2):460–469.
   PubMed Web of Science ®Google Scholar
• Vallon V, Gerasimova M, Rose MA, et al. SGLT2 inhibitor empagliflozin reduces renal growth and albuminuria in proportion to hyperglycemia and prevents glomerular hyperfiltration in diabetic Akita mice. Am J Physiol Renal Physiol. 2014;306(2):F194–F204.
   PubMed Web of Science ®Google Scholar
• Forbes JM, Cooper ME, Thallas V, et al. Reduction of the accumulation of advanced glycation end products by ACE inhibition in experimental diabetic nephropathy. Diabetes. 2002;51(11):3274–3282.
   PubMed Web of Science ®Google Scholar
• Ichihara A, Suzuki F, Nakagawa T, et al. Prorenin receptor blockade inhibits development of glomerulosclerosis in diabetic angiotensin II type 1a receptor-deficient mice. J Am Soc Nephrol. 2006;17(7):1950–1961.
   PubMed Web of Science ®Google Scholar
• Bornmann L, Daniel HD. What do citation counts measure? A review of studies on citing behavior. J Doc. 2008;64(1):45–80.
   Web of Science ®Google Scholar
• Thomas MC, Brownlee M, Susztak K, et al. Diabetic kidney disease. Nat Rev Dis Primers. 2015;1:15018.
   PubMed Web of Science ®Google Scholar
• Seglen PO. Why the impact factor of journals should not be used for evaluating research. BMJ (Clinical Research ed). 1997;314(7079):497–502.
   Google Scholar
• Garfield E. The history and meaning of the journal impact factor. JAMA. 2006;295(1):90–93.
   PubMed Web of Science ®Google Scholar
• Philipson L. Medical research activities, funding, and creativity in Europe: comparison with research in the United States. JAMA. 2005;294(11):1394–1398.
   PubMed Web of Science ®Google Scholar
• Reyes-Gonzalez L, Gonzalez-Brambila CN, Veloso F. Using co-authorship and citation analysis to identify research groups: a new way to assess performance. Scientometrics. 2016;108(3):1171–1191.
   Web of Science ®Google Scholar
• King AJ. The use of animal models in diabetes research. Br J Pharmacol. 2012;166(3):877–894.
   PubMed Web of Science ®Google Scholar
• Azushima K, Gurley SB, Coffman TM. Modelling diabetic nephropathy in mice. Nat Rev Nephrol. 2018;14(1):48–56.
   PubMed Web of Science ®Google Scholar
• Blonde L, Khunti K, Harris SB, et al. Interpretation and impact of real-world clinical data for the practicing clinician. Adv Ther. 2018;35(11):1763–1774.
   PubMed Web of Science ®Google Scholar
• Djulbegovic B, Guyatt GH. Progress in evidence-based medicine: a quarter century on. Lancet. 2017;390(10092):415–423.
   PubMed Web of Science ®Google Scholar
• American Diabetes Association. 11. Microvascular complications and foot care: standards of medical care in diabetes-2020. Diabetes Care. 2020;43(Suppl. 1):S135–S151.
   PubMedGoogle Scholar
• Perkovic V, Jardine MJ, Neal B, et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med. 2019;380(24):2295–2306.
   PubMed Web of Science ®Google Scholar
• Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group. KDIGO 2020 clinical practice guideline for diabetes management in chronic kidney disease. Kidney Int. 2020;98(4s):S1–S115.
   PubMedGoogle Scholar
• Sharma K, McGowan TA. TGF-beta in diabetic kidney disease: role of novel signaling pathways. Cytokine Growth Factor Rev. 2000;11(1–2):115–123.
   PubMed Web of Science ®Google Scholar
• Gewin LS. TGF-β and diabetic nephropathy: lessons learned over the past 20 years. Am J Med Sci. 2020;359(2):70–72.
   PubMed Web of Science ®Google Scholar
• Jha JC, Banal C, Chow BS, et al. Diabetes and kidney disease: role of oxidative stress. Antioxid Redox Signal. 2016;25(12):657–684.
   PubMed Web of Science ®Google Scholar
• Palmer SC, Mavridis D, Navarese E, et al. Comparative efficacy and safety of blood pressure-lowering agents in adults with diabetes and kidney disease: a network meta-analysis. Lancet. 2015;385(9982):2047–2056.
   PubMed Web of Science ®Google Scholar
• Van Buren PN, Toto RD. The pathogenesis and management of hypertension in diabetic kidney disease. Med Clin North Am. 2013;97(1):31–51.
   PubMed Web of Science ®Google Scholar
• Zou LX, Sun L. Global diabetic kidney disease research from 2000 to 2017: a bibliometric analysis. Medicine (Baltimore). 2019;98(6):e14394.
   PubMed Web of Science ®Google Scholar
• Barrera-Chimal J, Jaisser F. Pathophysiologic mechanisms in diabetic kidney disease: a focus on current and future therapeutic targets. Diabetes Obes Metab. 2020;22(Suppl. 1):16–31.
   PubMedGoogle Scholar
• Dumont JE. The bias of citations. Trends Biochem Sci. 1989;14(8):327–328.
   PubMed Web of Science ®Google Scholar